Autonomy is not a binary option, Bryant said in the first part of this video interview with PharmTech ®, and can work in ...

The field of cancer treatment saw a variety of advancements in 2025, from new dedicated centers to approved treatments to ...

Digital GMP expectations are increasing, driven by Annex 11 and Annex 22, necessitating robust lifecycle management, data ...

The top 10 PharmTech videos of the year cover advanced therapies, high-concentration biologics, major mergers and ...

The year 2025 was defined by escalating global trade tensions that fundamentally reshaped the pharmaceutical supply chain, ...

In an expansion of his written three-part series for PharmTech, Jason Bryant of ArisGlobal explains the interplay between ...

Multiple departments, including engineering and quality assurance, are responsible for evaluating GMP equipment and ...

AstraZeneca's MFN pricing agreement with the US government reflects broader efforts to reduce drug prices and enhance ...

From a global regulatory perspective, Cytokinetics is expanding its footprint rapidly. The drug received approval in China on ...

The revised EU pharmaceutical policy maintains eight-year data protection but reduces market protection to one year, ...

Mike Stenberg, LGM Pharma, outlines how GLP-1s, AI, and 505(b)(2) delivery shifts are driving pharmaceutical innovation.

André Cerbe, CEO of Schlafender Hase, spoke with Pharmaceutical Technology® about the disruptions the pharma industry faced ...